News from CEXS-UPF
Scientists at the Pompeu Fabra University, the Autonomous University of Madrid (UAM) and the IMDEA Nanoscience Institute are launching NANOCARD, a multidisciplinary project focused on developing nanoparticles for the diagnosis of cardiovascular lesions. The team led by Pilar Rivera Gil, researcher at the DCEXS, is determined to take advantage of the singularity of luminescent, magnetic and hybrid (optomagnetic) nanoparticles to fight against cardiovascular injuries.
Cardiovascular diseases are the leading cause of death worldwide. "It requires a great scientific-technological effort to develop techniques that allow a non-invasive diagnosis of the damage caused by cardiovascular diseases," says Rivera Gil, principal investigator of the project and leader of the group of research of Integrative Biomedical Materials and Nanomedicine at DCEXS . And adds, "These techniques will allow an effective evaluation of the type of injury and its response to the different treatments used."
"With NANOCARD we will manufacture biocompatible nanomaterials to improve in vivo imaging strategies and develop a pioneering system for the rapid detection of molecular markers in blood samples." NANOCARD will use nanoparticles to detect cardiovascular system injuries through its monitoring, selective accumulation and imaging of ischemic tissue and through the detection of molecular markers associated with cardiovascular damage in blood plasma. Following several strategies such as the use of optically active nanoparticles or magnetic nanoparticles that can act as contrast agents, NANOCARD aims to offer more efficient and sensitive alternatives than the techniques used today in the diagnosis of cardiovascular disease.